MAJI (Exousia Pro) Total Current Liabilities: $0.45 Mil (As of Jan. 2021)


What is Exousia Pro Total Current Liabilities?

Exousia Pro MAJI -1.92% Total Current Liabilities is $0.45 Mil as of Jan. 2021.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Exousia Pro's total current liabilities for the quarter that ended in Jan. 2021 was $0.45

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Exousia Pro Total Current Liabilities Related Terms

Exousia Pro Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Exousia Pro's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exousia Pro Total Current Liabilities Chart

Exousia Pro Annual Data
Trend Apr11 Apr12 Apr18 Apr19
Total Current Liabilities
0.10 0.28 0.09 0.21

Exousia Pro Quarterly Data
Oct11 Jan12 Apr12 Jul12 Oct12 Jan13 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.45 0.46 0.45 0.45

Exousia Pro Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Exousia Pro's Total Current Liabilities for the fiscal year that ended in Apr. 2019 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.207+0.008
+Other Current Liabilities+Current Deferred Liabilities
=-0.001+0
=0.21

Exousia Pro's Total Current Liabilities for the quarter that ended in Jan. 2021 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.198+0.247
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=0.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of $0.45 Mil mean?
Exousia Pro (MAJI) has a Total Current Liabilities of $0.45 Mil as of Jan. 2021. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Exousia Pro and its competitors.
Is Exousia Pro's Total Current Liabilities too high?
Exousia Pro's current Total Current Liabilities is $0.45 Mil.
How does Exousia Pro's Total Current Liabilities compare to HCCH and GRNV?
Exousia Pro's Total Current Liabilities of $0.45 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Exousia Pro and its competitors. Exousia Pro's current Total Current Liabilities is $0.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exousia Pro stock overvalued right now?
Exousia Pro (MAJI) has a current Total Current Liabilities of $0.45 Mil. The current Total Current Liabilities is $0.45 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Exousia Pro (MAJI), the current Total Current Liabilities is $0.45 Mil as of Jan. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Exousia Pro Business Description

Address 7901 4th Street North, No. 23494, St. Petersburg, FL, USA, 33702
Exousia Pro Inc is a exosome-based biotechnology, develops and manufactures mammalian and plant-based exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The company is developing new ways to exploit the therapeutic potential of exosomes, initially focused in the field of oncology. The platform technology of the company also helps treating a broad spectrum of viral infections.